Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States
- PMID: 6997738
- DOI: 10.1056/NEJM198010093031501
Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States
Abstract
We assessed the efficacy of an inactivated hepatitis B vaccine in a placebo-controlled, randomized, double-blind trial in 1083 homosexual men known to be at high risk for hepatitis B virus infection. The vaccine was found to be safe and the incidence of side effects was low. Within two months, 77% of the vaccinated persons had high levels of antibody against the hepatitis B surface antigen. This rate increased to 96% after the booster dose and remained essentially unchanged for the duration of the trial. For the first 18 months of follow-up, hepatitis B or subclinical infection developed in only 1.4 to 3.4% of the vaccine recipients as compared with 18 to 27% of placebo recipients (P < 0.0001). The reduction of incidence in the vaccinees was as high as 92.3%; none of the vaccinees with a detectable immune response to the vaccine had clinical hepatitis B or asymptomatic antigenemia. A significant reduction of incidence was already seen within 75 days after randomization; this observation suggests that the vaccine may be efficacious even when given after exposure.
Similar articles
-
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy.N Engl J Med. 1984 Aug 23;311(8):496-501. doi: 10.1056/NEJM198408233110803. N Engl J Med. 1984. PMID: 6235453 Clinical Trial.
-
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men.N Engl J Med. 1986 Jul 24;315(4):209-14. doi: 10.1056/NEJM198607243150401. N Engl J Med. 1986. PMID: 2941687 Clinical Trial.
-
Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection.N Engl J Med. 1982 Dec 9;307(24):1481-6. doi: 10.1056/NEJM198212093072403. N Engl J Med. 1982. PMID: 6755247 Clinical Trial.
-
Hepatitis virus vaccines: present status.Yale J Biol Med. 1982 May-Aug;55(3-4):375-81. Yale J Biol Med. 1982. PMID: 6295013 Free PMC article. Review.
-
Vaccination against hepatitis B in homosexual men. A review.Am J Med. 1989 Sep 4;87(3A):21S-25S. doi: 10.1016/0002-9343(89)90526-3. Am J Med. 1989. PMID: 2528293 Review.
Cited by
-
Translation of biomedical prevention strategies for HIV: prospects and pitfalls.J Acquir Immune Defic Syndr. 2013 Jun 1;63 Suppl 1(0 1):S12-25. doi: 10.1097/QAI.0b013e31829202a2. J Acquir Immune Defic Syndr. 2013. PMID: 23673881 Free PMC article. Review.
-
Protection of chimpanzees from type B hepatitis by immunization with woodchuck hepatitis virus surface antigen.J Virol. 1986 Dec;60(3):895-901. doi: 10.1128/JVI.60.3.895-901.1986. J Virol. 1986. PMID: 3783820 Free PMC article.
-
The cellular basis for lack of antibody response to hepatitis B vaccine in humans.J Exp Med. 1991 Mar 1;173(3):531-8. doi: 10.1084/jem.173.3.531. J Exp Med. 1991. PMID: 1825504 Free PMC article.
-
Adverse events after hepatitis B vaccination.CMAJ. 1992 Oct 1;147(7):1023-6. CMAJ. 1992. PMID: 1393898 Free PMC article. Review. No abstract available.
-
Presentation of an immunodominant T-cell epitope of hepatitis B surface antigen by the HLA-DPw4 molecule.J Virol. 1989 Feb;63(2):747-52. doi: 10.1128/JVI.63.2.747-752.1989. J Virol. 1989. PMID: 2463381 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
